Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib

on behalf of the Okayama Liver Cancer Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.

Original languageEnglish
JournalJournal of Gastroenterology and Hepatology (Australia)
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Angiopoietin-2
Hepatocellular Carcinoma
Cytokines
Survival
Serum
Hepatocyte Growth Factor
Hepatitis B Surface Antigens
Hepatitis B virus
Disease-Free Survival
Therapeutics
sorafenib

Keywords

  • angiopoietin-2
  • HCC
  • proangiogenic cytokines
  • sorafenib

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. / on behalf of the Okayama Liver Cancer Group.

In: Journal of Gastroenterology and Hepatology (Australia), 01.01.2018.

Research output: Contribution to journalArticle

@article{3e1f0d8fee4f4cb9ba7a662c8cbf5d7a,
title = "Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib",
abstract = "Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.",
keywords = "angiopoietin-2, HCC, proangiogenic cytokines, sorafenib",
author = "{on behalf of the Okayama Liver Cancer Group} and Takuya Adachi and Kazuhiro Nouso and Koji Miyahara and Atsushi Oyama and Nozomu Wada and Chihiro Dohi and Yasuto Takeuchi and Tetsuya Yasunaka and Hideki Ohnishi and Fusao Ikeda and Shinichiro Nakamura and Hidenori Shiraha and Akinobu Takaki and Hiroyuki Takabatake and Fujioka, {Shin ichi} and Haruhiko Kobashi and Yoshitaka Takuma and Shouta Iwadou and Shuji Uematsu and Koichi Takaguchi and Hiroaki Hagihara and Hiroyuki Okada",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jgh.14535",
language = "English",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib

AU - on behalf of the Okayama Liver Cancer Group

AU - Adachi, Takuya

AU - Nouso, Kazuhiro

AU - Miyahara, Koji

AU - Oyama, Atsushi

AU - Wada, Nozomu

AU - Dohi, Chihiro

AU - Takeuchi, Yasuto

AU - Yasunaka, Tetsuya

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Nakamura, Shinichiro

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Takabatake, Hiroyuki

AU - Fujioka, Shin ichi

AU - Kobashi, Haruhiko

AU - Takuma, Yoshitaka

AU - Iwadou, Shouta

AU - Uematsu, Shuji

AU - Takaguchi, Koichi

AU - Hagihara, Hiroaki

AU - Okada, Hiroyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.

AB - Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.

KW - angiopoietin-2

KW - HCC

KW - proangiogenic cytokines

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85058182251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058182251&partnerID=8YFLogxK

U2 - 10.1111/jgh.14535

DO - 10.1111/jgh.14535

M3 - Article

C2 - 30402928

AN - SCOPUS:85058182251

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

ER -